August Bioservices
San Carlos, CA
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
77.6
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: August Bioservices
- Signal Score
- 77.6/100 (as of 2026-10-29)
- Quality Compliance
- 98.8/100
- Headquarters
- San Carlos, CA
- Modalities
- AAV, Lentiviral
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About August Bioservices
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
98.8
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-04-18)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 manufacturing site: San Carlos, CA
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: San Carlos, CA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: San Carlos, CA
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
August Bioservices FDA Inspection History
2025-04
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2025-04-18 |
August Bioservices LLC
Nashville, Tennessee
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Frequently Asked Questions About August Bioservices
How many FDA inspections does August Bioservices have on record?
CDMO Signal tracks 1 FDA inspection for August Bioservices, sourced from the FDA inspection database. See the full inspection history above.
Has August Bioservices received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for August Bioservices.
What is August Bioservices's CDMO Signal Score?
August Bioservices has a Signal Score of 78/100, based on quality, operations, financial stability, and capacity data.
Evaluating August Bioservices for a manufacturing program?
Use the free AI matchmaker to compare August Bioservices against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
BioReliance (Merck)
Glasgow, UK · Rockville, MD
Signal Score: 80.3
AAV, Lentiviral, Biologics
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Compare August Bioservices with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.